Markets Stocks Economy Crypto Earnings Banking Energy
Home› Markets› Feature
Markets · Exclusive

Big Oil and biotech lead Monday's M&A headlines

Big Oil and biotech lead Monday's M&A headlines
Markets · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Nov 16, 2026 4 min read

Monday's dealmaking spotlight fell on two very different corners of the market: oil and gas and biotech. Canadian Natural Resources said it would acquire smaller Canadian producer Advantage Energy for C$2.53 billion including debt, while the Financial Times reported that Johnson & Johnson could announce a purchase of Texas-based Ollin Biosciences for up to $3.4 billion as soon as Monday.

The two headlines may seem unrelated, but they share a common thread: companies using acquisitions to buy growth rather than build it from scratch. In energy, that means snapping up producing wells and drilling inventory in the most attractive basins. In pharma, it means buying promising drug candidates to fill a pipeline that internal research alone may not sustain.

Energy deals add scale in key basins

Canadian Natural's move to buy Advantage Energy is the latest in a string of consolidation deals across North American oil and gas. The C$2.53 billion price tag, which includes debt, gives Canadian Natural access to Advantage's natural gas and oil assets in Western Canada. For a company already active in the region, the deal adds scale and extends its inventory of drilling locations.

Meanwhile, the Financial Times reported that Diamondback Energy is close to a roughly $5 billion purchase of a Double Eagle drilling portfolio in the Permian Basin, one of the most prolific oil-producing regions in the United States. That deal, if confirmed, would further concentrate ownership in the Permian, where larger operators are increasingly buying up smaller rivals to gain efficiency and lower costs per barrel.

These deals are part of a broader trend. Energy companies have been using strong cash flows from higher oil and gas prices to fund acquisitions rather than simply returning all profits to shareholders. The logic is that buying high-quality acreage is often cheaper and faster than drilling new wells from scratch, especially when the best locations are already held by someone else.

Biotech: J&J's reported target

On the biotech side, the Financial Times said Johnson & Johnson could announce a deal to buy Ollin Biosciences, a Texas-based company, for up to $3.4 billion. The report did not specify what Ollin's lead drug candidates target, but the price tag suggests it has assets that J&J sees as valuable additions to its pharmaceutical pipeline.

Large drugmakers routinely use acquisitions to bring in new medicines, especially in areas like oncology, immunology, and rare diseases. Internal research and development can be slow and risky, so buying a smaller company with a promising drug in late-stage trials can be a faster way to secure future revenue. This is a common pattern: when a big pharma company sees a gap in its portfolio, it often looks to buy a biotech that has already done the early-stage work.

For investors, the reported J&J deal is a reminder that M&A activity in biotech can be a catalyst for both the acquirer and the target. Shares of the target typically jump on news of a potential takeover, while the acquirer's stock may dip slightly as investors weigh the cost. But the long-term impact depends on whether the acquired drug ultimately wins approval and sells well.

What it means for investors

For markets, the Canadian Natural deal sets a new benchmark for how much buyers are willing to pay for oil and gas assets. Deals like this create a public "comparable" — a reference point that helps sellers and buyers agree on pricing. When a major producer pays a certain multiple for producing wells and undeveloped land, other companies holding similar assets may see their own valuations rise, even if they are not for sale.

That dynamic can lift the entire sector. If more acquirers keep paying up for high-quality acreage, it can raise expectations for other Canadian producers and for companies with Permian inventory. Investors holding energy stocks may benefit from this "bid tone," as it suggests that strategic buyers see value in the assets.

For biotech, the J&J story highlights the importance of M&A as a source of returns for smaller companies. Biotech stocks are often volatile, and a takeover offer can provide a significant premium to the market price. But not every reported deal comes to fruition, and investors should be cautious about acting on rumors alone.

Overall, Monday's headlines show that M&A remains a powerful force in both energy and healthcare. For everyday investors, the key takeaway is that acquisitions can reshape industries and create value — but they also carry risks, including integration challenges and the possibility that a deal falls through.

As always, it's wise to focus on the fundamentals of the companies you own, rather than chasing short-term deal news. If you're invested in a company that might be a target, a takeover premium can be a nice boost, but it's not a reason to buy a stock solely on speculation.

More from this story

Next article · Don't miss

TSX slides to six-week low as AI jitters hit tech shares

Canada's main stock index dropped to its lowest close in nearly six weeks, dragged down by tech and industrial shares as investors grew nervous ahead of Nvidia's earnings. Materials edged higher after Panama agreed to reopen talks on First Quantum's Cobre Pana

Read the story →
TSX slides to six-week low as AI jitters hit tech shares